Drug
Datopotamab Deruxtecan
Datopotamab Deruxtecan: highest development phase Phase 3, developed by AstraZeneca, Daiichi Sankyo. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AstraZeneca, Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| Datopotamab Deruxtecan NCT05555732 | Phase 3 | Metastatic Non Small Cell Lung Cancer |
| Datopotamab deruxtecan (Dato-DXd) NCT07291037 | Phase 3 | Non-small Cell Lung Cancer (NSCLC) |
Latest
No recent events.
Follow Datopotamab Deruxtecan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.